- Home
- KRC vs ACAD Comparison
KRC vs ACAD Comparison
Compare KRC & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRC
- ACAD
- Stock Information
- Founded
- KRC 1947
- ACAD 1993
- Country
- KRC United States
- ACAD United States
- Employees
- KRC N/A
- ACAD N/A
- Industry
- KRC Real Estate Investment Trusts
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- KRC Real Estate
- ACAD Health Care
- Exchange
- KRC Nasdaq
- ACAD Nasdaq
- Market Cap
- KRC 4.9B
- ACAD 4.3B
- IPO Year
- KRC 1997
- ACAD 2004
- Fundamental
- Price
- KRC $42.71
- ACAD $25.26
- Analyst Decision
- KRC Hold
- ACAD Buy
- Analyst Count
- KRC 11
- ACAD 20
- Target Price
- KRC $38.45
- ACAD $28.63
- AVG Volume (30 Days)
- KRC 1.2M
- ACAD 2.0M
- Earning Date
- KRC 10-27-2025
- ACAD 11-05-2025
- Dividend Yield
- KRC 5.06%
- ACAD N/A
- EPS Growth
- KRC 9.52
- ACAD 615.00
- EPS
- KRC 1.84
- ACAD 1.33
- Revenue
- KRC $1,137,053,000.00
- ACAD $1,018,885,000.00
- Revenue This Year
- KRC N/A
- ACAD $14.01
- Revenue Next Year
- KRC $0.73
- ACAD $11.72
- P/E Ratio
- KRC $23.21
- ACAD $19.05
- Revenue Growth
- KRC 2.26
- ACAD 14.41
- 52 Week Low
- KRC $27.07
- ACAD $13.40
- 52 Week High
- KRC $43.78
- ACAD $26.65
- Technical
- Relative Strength Index (RSI)
- KRC 71.10
- ACAD 54.05
- Support Level
- KRC $40.64
- ACAD $25.14
- Resistance Level
- KRC $41.88
- ACAD $26.50
- Average True Range (ATR)
- KRC 0.83
- ACAD 0.63
- MACD
- KRC 0.17
- ACAD -0.12
- Stochastic Oscillator
- KRC 99.78
- ACAD 36.24
About KRC Kilroy Realty Corporation
Kilroy Realty is a premier owner and landlord of approximately 17 million square feet of office space across Los Angeles, San Diego, the San Francisco Bay Area, Austin, Texas, and greater Seattle. The company operates as a real estate investment trust.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.